NeuroSense Therapeutics Ltd., a biotechnology company, announced on October 24, 2024, significant findings from its PARADIGM clinical trial for PrimeC, a treatment for ALS (Amyotrophic Lateral Sclerosis). The trial results showed that PrimeC significantly regulates key microRNAs (miRNAs) involved in ALS progression, offering new hope for treating the disease. PrimeC, an extended-release oral formulation combining ciprofloxacin and celecoxib, targets multiple key mechanisms of ALS. The trial included 68 participants across Canada, Italy, and Israel, with 96% choosing to continue PrimeC treatment after the 6-month double-blind portion. The data indicated a 29% difference in efficacy in favor of PrimeC over placebo, with a 37.4% slowing of disease progression observed. PrimeC has been granted Orphan Drug Designation by the FDA and the European Medicines Agency. NeuroSense is dedicated to developing treatments that address the root causes of neurodegenerative diseases and believes PrimeC's ability to regulate miRNAs is a significant step toward providing more therapeutic options for ALS patients.

NeuroSense Therapeutics Ltd., a biotechnology company, announced on October 24, 2024, significant findings from its PARADIGM clinical trial for PrimeC, a treatment for ALS (Amyotrophic Lateral Sclerosis). The trial results showed that PrimeC significantly regulates key microRNAs (miRNAs) involved in ALS progression, offering new hope for treating the disease. PrimeC, an extended-release oral formulation combining ciprofloxacin and celecoxib, targets multiple key mechanisms of ALS. The trial included 68 participants across Canada, Italy, and Israel, with 96% choosing to continue PrimeC treatment after the 6-month double-blind portion. The data indicated a 29% difference in efficacy in favor of PrimeC over placebo, with a 37.4% slowing of disease progression observed. PrimeC has been granted Orphan Drug Designation by the FDA and the European Medicines Agency. NeuroSense is dedicated to developing treatments that address the root causes of neurodegenerative diseases and believes PrimeC's ability to regulate miRNAs is a significant step toward providing more therapeutic options for ALS patients.